nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabilone—CNR2—Small Ligand GPCRs—PTGER4—skin cancer	0.0373	0.168	CbGpPWpGaD
Nabilone—CNR1—Small Ligand GPCRs—PTGER4—skin cancer	0.0293	0.131	CbGpPWpGaD
Nabilone—CNR1—GPCRs, Other—SMO—skin cancer	0.00858	0.0386	CbGpPWpGaD
Nabilone—CNR2—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00704	0.0316	CbGpPWpGaD
Nabilone—CNR2—GPCR ligand binding—PTCH2—skin cancer	0.00635	0.0285	CbGpPWpGaD
Nabilone—CNR2—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00603	0.0271	CbGpPWpGaD
Nabilone—CNR1—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00552	0.0248	CbGpPWpGaD
Nabilone—CNR1—GPCR ligand binding—PTCH2—skin cancer	0.00498	0.0224	CbGpPWpGaD
Nabilone—CNR1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00473	0.0213	CbGpPWpGaD
Nabilone—CNR2—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.00463	0.0208	CbGpPWpGaD
Nabilone—CNR2—GPCR ligand binding—MC1R—skin cancer	0.00459	0.0206	CbGpPWpGaD
Nabilone—CNR2—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.00396	0.0178	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—RHOU—skin cancer	0.00394	0.0177	CbGpPWpGaD
Nabilone—CNR1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.00363	0.0163	CbGpPWpGaD
Nabilone—CNR1—GPCR ligand binding—MC1R—skin cancer	0.0036	0.0162	CbGpPWpGaD
Nabilone—CNR2—GPCR ligand binding—SHH—skin cancer	0.00327	0.0147	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—PTCH2—skin cancer	0.00326	0.0146	CbGpPWpGaD
Nabilone—CNR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.00311	0.014	CbGpPWpGaD
Nabilone—CNR2—GPCR ligand binding—SMO—skin cancer	0.0031	0.0139	CbGpPWpGaD
Nabilone—CNR2—GPCR ligand binding—PTCH1—skin cancer	0.0031	0.0139	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—RHOU—skin cancer	0.00309	0.0139	CbGpPWpGaD
Nabilone—CNR2—GPCR ligand binding—PTGER4—skin cancer	0.00302	0.0136	CbGpPWpGaD
Nabilone—Decreased appetite—Vemurafenib—skin cancer	0.00263	0.00338	CcSEcCtD
Nabilone—Stomatitis—Dactinomycin—skin cancer	0.00261	0.00336	CcSEcCtD
Nabilone—Fatigue—Vemurafenib—skin cancer	0.00261	0.00335	CcSEcCtD
Nabilone—CNR2—GPCR downstream signaling—MC1R—skin cancer	0.00259	0.0117	CbGpPWpGaD
Nabilone—Constipation—Vemurafenib—skin cancer	0.00259	0.00333	CcSEcCtD
Nabilone—Lightheadedness—Docetaxel—skin cancer	0.00258	0.00332	CcSEcCtD
Nabilone—CNR1—GPCR ligand binding—SHH—skin cancer	0.00257	0.0115	CbGpPWpGaD
Nabilone—Hypoaesthesia—Bleomycin—skin cancer	0.00257	0.0033	CcSEcCtD
Nabilone—Infection—Imiquimod—skin cancer	0.00256	0.0033	CcSEcCtD
Nabilone—CNR1—Signaling by GPCR—PTCH2—skin cancer	0.00256	0.0115	CbGpPWpGaD
Nabilone—Shock—Imiquimod—skin cancer	0.00254	0.00326	CcSEcCtD
Nabilone—Tachycardia—Imiquimod—skin cancer	0.00252	0.00324	CcSEcCtD
Nabilone—Pollakiuria—Temozolomide—skin cancer	0.00251	0.00323	CcSEcCtD
Nabilone—Hyperhidrosis—Imiquimod—skin cancer	0.00249	0.00321	CcSEcCtD
Nabilone—Photosensitivity reaction—Temozolomide—skin cancer	0.00248	0.00319	CcSEcCtD
Nabilone—Anorexia—Imiquimod—skin cancer	0.00246	0.00316	CcSEcCtD
Nabilone—CNR1—GPCR ligand binding—SMO—skin cancer	0.00243	0.0109	CbGpPWpGaD
Nabilone—CNR1—GPCR ligand binding—PTCH1—skin cancer	0.00243	0.0109	CbGpPWpGaD
Nabilone—Depression—Temozolomide—skin cancer	0.00242	0.00311	CcSEcCtD
Nabilone—Flushing—Bleomycin—skin cancer	0.00239	0.00308	CcSEcCtD
Nabilone—Body temperature increased—Vemurafenib—skin cancer	0.00239	0.00308	CcSEcCtD
Nabilone—Pharyngitis—Dactinomycin—skin cancer	0.00239	0.00307	CcSEcCtD
Nabilone—CNR1—GPCR ligand binding—PTGER4—skin cancer	0.00237	0.0106	CbGpPWpGaD
Nabilone—Stomatitis—Temozolomide—skin cancer	0.00236	0.00304	CcSEcCtD
Nabilone—CNR2—Signaling by GPCR—MC1R—skin cancer	0.00236	0.0106	CbGpPWpGaD
Nabilone—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00235	0.00302	CcSEcCtD
Nabilone—Insomnia—Imiquimod—skin cancer	0.00233	0.003	CcSEcCtD
Nabilone—Paraesthesia—Imiquimod—skin cancer	0.00232	0.00298	CcSEcCtD
Nabilone—Chills—Bleomycin—skin cancer	0.00231	0.00298	CcSEcCtD
Nabilone—Dyspnoea—Imiquimod—skin cancer	0.0023	0.00296	CcSEcCtD
Nabilone—Somnolence—Imiquimod—skin cancer	0.00229	0.00295	CcSEcCtD
Nabilone—Photosensitivity reaction—Fluorouracil—skin cancer	0.00229	0.00294	CcSEcCtD
Nabilone—Dyspepsia—Imiquimod—skin cancer	0.00227	0.00292	CcSEcCtD
Nabilone—Decreased appetite—Imiquimod—skin cancer	0.00224	0.00288	CcSEcCtD
Nabilone—Hot flush—Docetaxel—skin cancer	0.00224	0.00288	CcSEcCtD
Nabilone—Flushing—Dactinomycin—skin cancer	0.00223	0.00287	CcSEcCtD
Nabilone—Hypersensitivity—Vemurafenib—skin cancer	0.00223	0.00287	CcSEcCtD
Nabilone—Fatigue—Imiquimod—skin cancer	0.00222	0.00286	CcSEcCtD
Nabilone—Menopausal symptoms—Docetaxel—skin cancer	0.00222	0.00285	CcSEcCtD
Nabilone—Visual disturbance—Docetaxel—skin cancer	0.00221	0.00284	CcSEcCtD
Nabilone—Pain—Imiquimod—skin cancer	0.00221	0.00284	CcSEcCtD
Nabilone—Stomatitis—Fluorouracil—skin cancer	0.00218	0.0028	CcSEcCtD
Nabilone—Asthenia—Vemurafenib—skin cancer	0.00217	0.00279	CcSEcCtD
Nabilone—Hallucination—Temozolomide—skin cancer	0.00216	0.00278	CcSEcCtD
Nabilone—Hypoaesthesia—Temozolomide—skin cancer	0.00216	0.00278	CcSEcCtD
Nabilone—Pharyngitis—Temozolomide—skin cancer	0.00216	0.00278	CcSEcCtD
Nabilone—Chills—Dactinomycin—skin cancer	0.00216	0.00278	CcSEcCtD
Nabilone—Pruritus—Vemurafenib—skin cancer	0.00214	0.00275	CcSEcCtD
Nabilone—Feeling abnormal—Imiquimod—skin cancer	0.00213	0.00273	CcSEcCtD
Nabilone—Gastrointestinal pain—Imiquimod—skin cancer	0.00211	0.00271	CcSEcCtD
Nabilone—Epistaxis—Fluorouracil—skin cancer	0.00211	0.00271	CcSEcCtD
Nabilone—Visual impairment—Temozolomide—skin cancer	0.0021	0.0027	CcSEcCtD
Nabilone—Ill-defined disorder—Bleomycin—skin cancer	0.00208	0.00268	CcSEcCtD
Nabilone—Anaemia—Bleomycin—skin cancer	0.00208	0.00267	CcSEcCtD
Nabilone—Diarrhoea—Vemurafenib—skin cancer	0.00207	0.00266	CcSEcCtD
Nabilone—Abdominal pain—Imiquimod—skin cancer	0.00204	0.00262	CcSEcCtD
Nabilone—Body temperature increased—Imiquimod—skin cancer	0.00204	0.00262	CcSEcCtD
Nabilone—CNR1—GPCR downstream signaling—MC1R—skin cancer	0.00204	0.00915	CbGpPWpGaD
Nabilone—Eye disorder—Temozolomide—skin cancer	0.00203	0.00262	CcSEcCtD
Nabilone—Tinnitus—Temozolomide—skin cancer	0.00203	0.00261	CcSEcCtD
Nabilone—Malaise—Bleomycin—skin cancer	0.00202	0.0026	CcSEcCtD
Nabilone—Flushing—Temozolomide—skin cancer	0.00202	0.0026	CcSEcCtD
Nabilone—Leukopenia—Bleomycin—skin cancer	0.00201	0.00258	CcSEcCtD
Nabilone—Dizziness—Vemurafenib—skin cancer	0.002	0.00257	CcSEcCtD
Nabilone—Hypoaesthesia—Fluorouracil—skin cancer	0.00199	0.00257	CcSEcCtD
Nabilone—Pharyngitis—Fluorouracil—skin cancer	0.00199	0.00256	CcSEcCtD
Nabilone—Ataxia—Docetaxel—skin cancer	0.00197	0.00253	CcSEcCtD
Nabilone—Cough—Bleomycin—skin cancer	0.00196	0.00252	CcSEcCtD
Nabilone—Chills—Temozolomide—skin cancer	0.00195	0.00251	CcSEcCtD
Nabilone—Ill-defined disorder—Dactinomycin—skin cancer	0.00194	0.0025	CcSEcCtD
Nabilone—Anaemia—Dactinomycin—skin cancer	0.00194	0.00249	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—PTCH2—skin cancer	0.00192	0.00865	CbGpPWpGaD
Nabilone—Vomiting—Vemurafenib—skin cancer	0.00192	0.00247	CcSEcCtD
Nabilone—Myalgia—Bleomycin—skin cancer	0.00191	0.00246	CcSEcCtD
Nabilone—Chest pain—Bleomycin—skin cancer	0.00191	0.00246	CcSEcCtD
Nabilone—Orthostatic hypotension—Docetaxel—skin cancer	0.00191	0.00246	CcSEcCtD
Nabilone—Rash—Vemurafenib—skin cancer	0.00191	0.00245	CcSEcCtD
Nabilone—Dermatitis—Vemurafenib—skin cancer	0.00191	0.00245	CcSEcCtD
Nabilone—Hypersensitivity—Imiquimod—skin cancer	0.0019	0.00244	CcSEcCtD
Nabilone—Headache—Vemurafenib—skin cancer	0.00189	0.00244	CcSEcCtD
Nabilone—Discomfort—Bleomycin—skin cancer	0.00189	0.00243	CcSEcCtD
Nabilone—Malaise—Dactinomycin—skin cancer	0.00189	0.00243	CcSEcCtD
Nabilone—Leukopenia—Dactinomycin—skin cancer	0.00187	0.00241	CcSEcCtD
Nabilone—Asthenia—Imiquimod—skin cancer	0.00185	0.00238	CcSEcCtD
Nabilone—CNR1—Signaling by GPCR—MC1R—skin cancer	0.00185	0.00831	CbGpPWpGaD
Nabilone—Confusional state—Bleomycin—skin cancer	0.00185	0.00238	CcSEcCtD
Nabilone—Back pain—Temozolomide—skin cancer	0.00183	0.00236	CcSEcCtD
Nabilone—Pruritus—Imiquimod—skin cancer	0.00182	0.00235	CcSEcCtD
Nabilone—Infection—Bleomycin—skin cancer	0.00182	0.00234	CcSEcCtD
Nabilone—Nausea—Vemurafenib—skin cancer	0.0018	0.00231	CcSEcCtD
Nabilone—Arrhythmia—Fluorouracil—skin cancer	0.00179	0.0023	CcSEcCtD
Nabilone—Vision blurred—Temozolomide—skin cancer	0.00178	0.0023	CcSEcCtD
Nabilone—Myalgia—Dactinomycin—skin cancer	0.00178	0.00229	CcSEcCtD
Nabilone—Tremor—Temozolomide—skin cancer	0.00177	0.00228	CcSEcCtD
Nabilone—Diarrhoea—Imiquimod—skin cancer	0.00176	0.00227	CcSEcCtD
Nabilone—Discomfort—Dactinomycin—skin cancer	0.00176	0.00227	CcSEcCtD
Nabilone—Ill-defined disorder—Temozolomide—skin cancer	0.00176	0.00226	CcSEcCtD
Nabilone—Anaemia—Temozolomide—skin cancer	0.00175	0.00225	CcSEcCtD
Nabilone—Anorexia—Bleomycin—skin cancer	0.00175	0.00225	CcSEcCtD
Nabilone—Agitation—Temozolomide—skin cancer	0.00174	0.00224	CcSEcCtD
Nabilone—Hypotension—Bleomycin—skin cancer	0.00171	0.0022	CcSEcCtD
Nabilone—Malaise—Temozolomide—skin cancer	0.00171	0.0022	CcSEcCtD
Nabilone—CNR2—GPCR downstream signaling—PTGER4—skin cancer	0.00171	0.00766	CbGpPWpGaD
Nabilone—Dizziness—Imiquimod—skin cancer	0.00171	0.00219	CcSEcCtD
Nabilone—Vertigo—Temozolomide—skin cancer	0.0017	0.00219	CcSEcCtD
Nabilone—Infection—Dactinomycin—skin cancer	0.0017	0.00218	CcSEcCtD
Nabilone—Leukopenia—Temozolomide—skin cancer	0.0017	0.00218	CcSEcCtD
Nabilone—CNR2—Signaling by GPCR—SHH—skin cancer	0.00168	0.00754	CbGpPWpGaD
Nabilone—Palpitations—Temozolomide—skin cancer	0.00167	0.00215	CcSEcCtD
Nabilone—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00167	0.00215	CcSEcCtD
Nabilone—Cough—Temozolomide—skin cancer	0.00165	0.00213	CcSEcCtD
Nabilone—Paraesthesia—Bleomycin—skin cancer	0.00165	0.00212	CcSEcCtD
Nabilone—Vision blurred—Fluorouracil—skin cancer	0.00164	0.00212	CcSEcCtD
Nabilone—Convulsion—Temozolomide—skin cancer	0.00164	0.00211	CcSEcCtD
Nabilone—Vomiting—Imiquimod—skin cancer	0.00164	0.00211	CcSEcCtD
Nabilone—Hypertension—Temozolomide—skin cancer	0.00164	0.0021	CcSEcCtD
Nabilone—Dyspnoea—Bleomycin—skin cancer	0.00163	0.0021	CcSEcCtD
Nabilone—Anorexia—Dactinomycin—skin cancer	0.00163	0.0021	CcSEcCtD
Nabilone—Rash—Imiquimod—skin cancer	0.00163	0.00209	CcSEcCtD
Nabilone—Dermatitis—Imiquimod—skin cancer	0.00162	0.00209	CcSEcCtD
Nabilone—Headache—Imiquimod—skin cancer	0.00162	0.00208	CcSEcCtD
Nabilone—Anaemia—Fluorouracil—skin cancer	0.00161	0.00207	CcSEcCtD
Nabilone—Myalgia—Temozolomide—skin cancer	0.00161	0.00207	CcSEcCtD
Nabilone—Arthralgia—Temozolomide—skin cancer	0.00161	0.00207	CcSEcCtD
Nabilone—Anxiety—Temozolomide—skin cancer	0.00161	0.00207	CcSEcCtD
Nabilone—Discomfort—Temozolomide—skin cancer	0.00159	0.00205	CcSEcCtD
Nabilone—Decreased appetite—Bleomycin—skin cancer	0.00159	0.00205	CcSEcCtD
Nabilone—CNR2—Signaling by GPCR—PTCH1—skin cancer	0.00159	0.00715	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—SMO—skin cancer	0.00159	0.00715	CbGpPWpGaD
Nabilone—Dry mouth—Temozolomide—skin cancer	0.00158	0.00203	CcSEcCtD
Nabilone—Stomatitis—Docetaxel—skin cancer	0.00157	0.00202	CcSEcCtD
Nabilone—Pain—Bleomycin—skin cancer	0.00157	0.00202	CcSEcCtD
Nabilone—Leukopenia—Fluorouracil—skin cancer	0.00156	0.00201	CcSEcCtD
Nabilone—Confusional state—Temozolomide—skin cancer	0.00156	0.002	CcSEcCtD
Nabilone—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00156	0.002	CcSEcCtD
Nabilone—CNR2—Signaling by GPCR—PTGER4—skin cancer	0.00155	0.00696	CbGpPWpGaD
Nabilone—Infection—Temozolomide—skin cancer	0.00154	0.00198	CcSEcCtD
Nabilone—Nausea—Imiquimod—skin cancer	0.00153	0.00197	CcSEcCtD
Nabilone—Epistaxis—Docetaxel—skin cancer	0.00152	0.00196	CcSEcCtD
Nabilone—Convulsion—Fluorouracil—skin cancer	0.00151	0.00194	CcSEcCtD
Nabilone—CNR1—Signaling Pathways—PTCH2—skin cancer	0.00151	0.00679	CbGpPWpGaD
Nabilone—Feeling abnormal—Bleomycin—skin cancer	0.00151	0.00194	CcSEcCtD
Nabilone—Hyperhidrosis—Temozolomide—skin cancer	0.00149	0.00192	CcSEcCtD
Nabilone—Chest pain—Fluorouracil—skin cancer	0.00149	0.00191	CcSEcCtD
Nabilone—Myalgia—Fluorouracil—skin cancer	0.00149	0.00191	CcSEcCtD
Nabilone—Decreased appetite—Dactinomycin—skin cancer	0.00149	0.00191	CcSEcCtD
Nabilone—Fatigue—Dactinomycin—skin cancer	0.00147	0.0019	CcSEcCtD
Nabilone—Anorexia—Temozolomide—skin cancer	0.00147	0.0019	CcSEcCtD
Nabilone—Discomfort—Fluorouracil—skin cancer	0.00147	0.00189	CcSEcCtD
Nabilone—Pain—Dactinomycin—skin cancer	0.00146	0.00188	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—GLI2—skin cancer	0.00146	0.00655	CbGpPWpGaD
Nabilone—Body temperature increased—Bleomycin—skin cancer	0.00145	0.00186	CcSEcCtD
Nabilone—Hypoaesthesia—Docetaxel—skin cancer	0.00144	0.00185	CcSEcCtD
Nabilone—Confusional state—Fluorouracil—skin cancer	0.00144	0.00185	CcSEcCtD
Nabilone—Pharyngitis—Docetaxel—skin cancer	0.00144	0.00185	CcSEcCtD
Nabilone—Infection—Fluorouracil—skin cancer	0.00141	0.00182	CcSEcCtD
Nabilone—Feeling abnormal—Dactinomycin—skin cancer	0.00141	0.00181	CcSEcCtD
Nabilone—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00141	0.00181	CcSEcCtD
Nabilone—Insomnia—Temozolomide—skin cancer	0.0014	0.0018	CcSEcCtD
Nabilone—Gastrointestinal pain—Dactinomycin—skin cancer	0.0014	0.0018	CcSEcCtD
Nabilone—Visual impairment—Docetaxel—skin cancer	0.00139	0.00179	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—MC1R—skin cancer	0.00139	0.00625	CbGpPWpGaD
Nabilone—Tachycardia—Fluorouracil—skin cancer	0.00139	0.00179	CcSEcCtD
Nabilone—Paraesthesia—Temozolomide—skin cancer	0.00139	0.00179	CcSEcCtD
Nabilone—Dyspnoea—Temozolomide—skin cancer	0.00138	0.00177	CcSEcCtD
Nabilone—Somnolence—Temozolomide—skin cancer	0.00137	0.00177	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—GLI1—skin cancer	0.00137	0.00616	CbGpPWpGaD
Nabilone—Dyspepsia—Temozolomide—skin cancer	0.00136	0.00175	CcSEcCtD
Nabilone—Anorexia—Fluorouracil—skin cancer	0.00136	0.00175	CcSEcCtD
Nabilone—Eye disorder—Docetaxel—skin cancer	0.00135	0.00174	CcSEcCtD
Nabilone—Abdominal pain—Dactinomycin—skin cancer	0.00135	0.00174	CcSEcCtD
Nabilone—Body temperature increased—Dactinomycin—skin cancer	0.00135	0.00174	CcSEcCtD
Nabilone—Hypersensitivity—Bleomycin—skin cancer	0.00135	0.00174	CcSEcCtD
Nabilone—Decreased appetite—Temozolomide—skin cancer	0.00134	0.00173	CcSEcCtD
Nabilone—Flushing—Docetaxel—skin cancer	0.00134	0.00173	CcSEcCtD
Nabilone—CNR1—GPCR downstream signaling—PTGER4—skin cancer	0.00134	0.00601	CbGpPWpGaD
Nabilone—Fatigue—Temozolomide—skin cancer	0.00133	0.00171	CcSEcCtD
Nabilone—Hypotension—Fluorouracil—skin cancer	0.00133	0.00171	CcSEcCtD
Nabilone—Constipation—Temozolomide—skin cancer	0.00132	0.0017	CcSEcCtD
Nabilone—Pain—Temozolomide—skin cancer	0.00132	0.0017	CcSEcCtD
Nabilone—CNR1—Signaling by GPCR—SHH—skin cancer	0.00132	0.00592	CbGpPWpGaD
Nabilone—Asthenia—Bleomycin—skin cancer	0.00131	0.00169	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—SUFU—skin cancer	0.0013	0.00584	CbGpPWpGaD
Nabilone—Chills—Docetaxel—skin cancer	0.0013	0.00167	CcSEcCtD
Nabilone—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.0013	0.00167	CcSEcCtD
Nabilone—Pruritus—Bleomycin—skin cancer	0.0013	0.00167	CcSEcCtD
Nabilone—Arrhythmia—Docetaxel—skin cancer	0.00129	0.00166	CcSEcCtD
Nabilone—Insomnia—Fluorouracil—skin cancer	0.00129	0.00166	CcSEcCtD
Nabilone—Paraesthesia—Fluorouracil—skin cancer	0.00128	0.00164	CcSEcCtD
Nabilone—Feeling abnormal—Temozolomide—skin cancer	0.00127	0.00164	CcSEcCtD
Nabilone—Dyspnoea—Fluorouracil—skin cancer	0.00127	0.00163	CcSEcCtD
Nabilone—Somnolence—Fluorouracil—skin cancer	0.00127	0.00163	CcSEcCtD
Nabilone—Gastrointestinal pain—Temozolomide—skin cancer	0.00126	0.00163	CcSEcCtD
Nabilone—Hypersensitivity—Dactinomycin—skin cancer	0.00126	0.00162	CcSEcCtD
Nabilone—Dyspepsia—Fluorouracil—skin cancer	0.00125	0.00161	CcSEcCtD
Nabilone—CNR1—Signaling by GPCR—SMO—skin cancer	0.00125	0.00561	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—PTCH1—skin cancer	0.00125	0.00561	CbGpPWpGaD
Nabilone—CNR1—BDNF signaling pathway—HRAS—skin cancer	0.00124	0.00559	CbGpPWpGaD
Nabilone—Decreased appetite—Fluorouracil—skin cancer	0.00124	0.00159	CcSEcCtD
Nabilone—Asthenia—Dactinomycin—skin cancer	0.00123	0.00158	CcSEcCtD
Nabilone—Body temperature increased—Temozolomide—skin cancer	0.00122	0.00157	CcSEcCtD
Nabilone—Abdominal pain—Temozolomide—skin cancer	0.00122	0.00157	CcSEcCtD
Nabilone—Back pain—Docetaxel—skin cancer	0.00122	0.00157	CcSEcCtD
Nabilone—Pain—Fluorouracil—skin cancer	0.00122	0.00157	CcSEcCtD
Nabilone—CNR1—Signaling by GPCR—PTGER4—skin cancer	0.00122	0.00546	CbGpPWpGaD
Nabilone—Feeling abnormal—Fluorouracil—skin cancer	0.00117	0.00151	CcSEcCtD
Nabilone—Diarrhoea—Dactinomycin—skin cancer	0.00117	0.0015	CcSEcCtD
Nabilone—Vomiting—Bleomycin—skin cancer	0.00116	0.0015	CcSEcCtD
Nabilone—Anaemia—Docetaxel—skin cancer	0.00116	0.0015	CcSEcCtD
Nabilone—Rash—Bleomycin—skin cancer	0.00116	0.00149	CcSEcCtD
Nabilone—Dermatitis—Bleomycin—skin cancer	0.00115	0.00148	CcSEcCtD
Nabilone—CNR1—Signaling Pathways—GLI2—skin cancer	0.00114	0.00514	CbGpPWpGaD
Nabilone—Hypersensitivity—Temozolomide—skin cancer	0.00114	0.00146	CcSEcCtD
Nabilone—Syncope—Docetaxel—skin cancer	0.00113	0.00145	CcSEcCtD
Nabilone—Leukopenia—Docetaxel—skin cancer	0.00113	0.00145	CcSEcCtD
Nabilone—Body temperature increased—Fluorouracil—skin cancer	0.00113	0.00145	CcSEcCtD
Nabilone—Palpitations—Docetaxel—skin cancer	0.00111	0.00143	CcSEcCtD
Nabilone—Asthenia—Temozolomide—skin cancer	0.00111	0.00143	CcSEcCtD
Nabilone—Loss of consciousness—Docetaxel—skin cancer	0.00111	0.00142	CcSEcCtD
Nabilone—Cough—Docetaxel—skin cancer	0.0011	0.00141	CcSEcCtD
Nabilone—Pruritus—Temozolomide—skin cancer	0.00109	0.00141	CcSEcCtD
Nabilone—CNR1—Signaling Pathways—MC1R—skin cancer	0.00109	0.00491	CbGpPWpGaD
Nabilone—Convulsion—Docetaxel—skin cancer	0.00109	0.0014	CcSEcCtD
Nabilone—Nausea—Bleomycin—skin cancer	0.00109	0.0014	CcSEcCtD
Nabilone—Hypertension—Docetaxel—skin cancer	0.00109	0.0014	CcSEcCtD
Nabilone—Vomiting—Dactinomycin—skin cancer	0.00109	0.0014	CcSEcCtD
Nabilone—Rash—Dactinomycin—skin cancer	0.00108	0.00139	CcSEcCtD
Nabilone—CNR1—Signaling Pathways—GLI1—skin cancer	0.00108	0.00484	CbGpPWpGaD
Nabilone—Myalgia—Docetaxel—skin cancer	0.00107	0.00138	CcSEcCtD
Nabilone—Arthralgia—Docetaxel—skin cancer	0.00107	0.00138	CcSEcCtD
Nabilone—Chest pain—Docetaxel—skin cancer	0.00107	0.00138	CcSEcCtD
Nabilone—Diarrhoea—Temozolomide—skin cancer	0.00106	0.00136	CcSEcCtD
Nabilone—Hypersensitivity—Fluorouracil—skin cancer	0.00105	0.00135	CcSEcCtD
Nabilone—Dry mouth—Docetaxel—skin cancer	0.00105	0.00135	CcSEcCtD
Nabilone—Confusional state—Docetaxel—skin cancer	0.00104	0.00133	CcSEcCtD
Nabilone—Dizziness—Temozolomide—skin cancer	0.00102	0.00131	CcSEcCtD
Nabilone—Infection—Docetaxel—skin cancer	0.00102	0.00131	CcSEcCtD
Nabilone—CNR1—Signaling Pathways—SUFU—skin cancer	0.00102	0.00458	CbGpPWpGaD
Nabilone—Nausea—Dactinomycin—skin cancer	0.00102	0.00131	CcSEcCtD
Nabilone—Shock—Docetaxel—skin cancer	0.00101	0.0013	CcSEcCtD
Nabilone—Pruritus—Fluorouracil—skin cancer	0.00101	0.0013	CcSEcCtD
Nabilone—Tachycardia—Docetaxel—skin cancer	0.001	0.00129	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—SHH—skin cancer	0.000992	0.00446	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—RASA1—skin cancer	0.000985	0.00443	CbGpPWpGaD
Nabilone—Vomiting—Temozolomide—skin cancer	0.000983	0.00126	CcSEcCtD
Nabilone—Anorexia—Docetaxel—skin cancer	0.00098	0.00126	CcSEcCtD
Nabilone—Rash—Temozolomide—skin cancer	0.000975	0.00125	CcSEcCtD
Nabilone—Diarrhoea—Fluorouracil—skin cancer	0.000974	0.00125	CcSEcCtD
Nabilone—Dermatitis—Temozolomide—skin cancer	0.000974	0.00125	CcSEcCtD
Nabilone—Headache—Temozolomide—skin cancer	0.000968	0.00125	CcSEcCtD
Nabilone—Hypotension—Docetaxel—skin cancer	0.00096	0.00124	CcSEcCtD
Nabilone—Dizziness—Fluorouracil—skin cancer	0.000942	0.00121	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—SMO—skin cancer	0.00094	0.00422	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—PTCH1—skin cancer	0.00094	0.00422	CbGpPWpGaD
Nabilone—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000936	0.0012	CcSEcCtD
Nabilone—Insomnia—Docetaxel—skin cancer	0.00093	0.0012	CcSEcCtD
Nabilone—Paraesthesia—Docetaxel—skin cancer	0.000923	0.00119	CcSEcCtD
Nabilone—Nausea—Temozolomide—skin cancer	0.000918	0.00118	CcSEcCtD
Nabilone—Dyspnoea—Docetaxel—skin cancer	0.000916	0.00118	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—PTGER4—skin cancer	0.000915	0.00411	CbGpPWpGaD
Nabilone—Somnolence—Docetaxel—skin cancer	0.000914	0.00118	CcSEcCtD
Nabilone—Vomiting—Fluorouracil—skin cancer	0.000905	0.00116	CcSEcCtD
Nabilone—Dyspepsia—Docetaxel—skin cancer	0.000905	0.00116	CcSEcCtD
Nabilone—Rash—Fluorouracil—skin cancer	0.000898	0.00115	CcSEcCtD
Nabilone—Dermatitis—Fluorouracil—skin cancer	0.000897	0.00115	CcSEcCtD
Nabilone—Decreased appetite—Docetaxel—skin cancer	0.000893	0.00115	CcSEcCtD
Nabilone—Headache—Fluorouracil—skin cancer	0.000892	0.00115	CcSEcCtD
Nabilone—Fatigue—Docetaxel—skin cancer	0.000886	0.00114	CcSEcCtD
Nabilone—Pain—Docetaxel—skin cancer	0.000879	0.00113	CcSEcCtD
Nabilone—Constipation—Docetaxel—skin cancer	0.000879	0.00113	CcSEcCtD
Nabilone—Feeling abnormal—Docetaxel—skin cancer	0.000847	0.00109	CcSEcCtD
Nabilone—Nausea—Fluorouracil—skin cancer	0.000846	0.00109	CcSEcCtD
Nabilone—Gastrointestinal pain—Docetaxel—skin cancer	0.00084	0.00108	CcSEcCtD
Nabilone—Body temperature increased—Docetaxel—skin cancer	0.000813	0.00105	CcSEcCtD
Nabilone—Abdominal pain—Docetaxel—skin cancer	0.000813	0.00105	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—FOXO4—skin cancer	0.000808	0.00363	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—SHH—skin cancer	0.000778	0.0035	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—RASA1—skin cancer	0.000773	0.00347	CbGpPWpGaD
Nabilone—Hypersensitivity—Docetaxel—skin cancer	0.000757	0.000974	CcSEcCtD
Nabilone—CNR1—Signaling Pathways—SMO—skin cancer	0.000738	0.00331	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—PTCH1—skin cancer	0.000738	0.00331	CbGpPWpGaD
Nabilone—Asthenia—Docetaxel—skin cancer	0.000737	0.000949	CcSEcCtD
Nabilone—Pruritus—Docetaxel—skin cancer	0.000727	0.000935	CcSEcCtD
Nabilone—CNR1—Signaling Pathways—PTGER4—skin cancer	0.000718	0.00323	CbGpPWpGaD
Nabilone—Diarrhoea—Docetaxel—skin cancer	0.000703	0.000905	CcSEcCtD
Nabilone—Dizziness—Docetaxel—skin cancer	0.00068	0.000874	CcSEcCtD
Nabilone—Vomiting—Docetaxel—skin cancer	0.000654	0.000841	CcSEcCtD
Nabilone—Rash—Docetaxel—skin cancer	0.000648	0.000834	CcSEcCtD
Nabilone—Dermatitis—Docetaxel—skin cancer	0.000647	0.000833	CcSEcCtD
Nabilone—Headache—Docetaxel—skin cancer	0.000644	0.000828	CcSEcCtD
Nabilone—CNR1—Signaling Pathways—FOXO4—skin cancer	0.000634	0.00285	CbGpPWpGaD
Nabilone—Nausea—Docetaxel—skin cancer	0.000611	0.000785	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—TERT—skin cancer	0.00054	0.00243	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—NRAS—skin cancer	0.000455	0.00204	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—BRAF—skin cancer	0.000428	0.00192	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—TERT—skin cancer	0.000424	0.0019	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—KRAS—skin cancer	0.000391	0.00176	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—NRAS—skin cancer	0.000357	0.0016	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—BRAF—skin cancer	0.000336	0.00151	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—HRAS—skin cancer	0.000333	0.0015	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—IL6—skin cancer	0.000318	0.00143	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—KRAS—skin cancer	0.000307	0.00138	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—NRAS—skin cancer	0.000269	0.00121	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—HRAS—skin cancer	0.000261	0.00117	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—IL6—skin cancer	0.00025	0.00112	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—KRAS—skin cancer	0.000231	0.00104	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—NRAS—skin cancer	0.000211	0.000947	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—TP53—skin cancer	0.000206	0.000924	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—HRAS—skin cancer	0.000197	0.000883	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—IL6—skin cancer	0.000188	0.000845	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—KRAS—skin cancer	0.000181	0.000815	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—TP53—skin cancer	0.000161	0.000725	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—HRAS—skin cancer	0.000154	0.000693	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—IL6—skin cancer	0.000148	0.000663	CbGpPWpGaD
